Uni-Bio Science Group Limited — Environmental & Social Information 2021

May 11, 2021

==> picture [197 x 37] intentionally omitted <==

G

==> picture [198 x 110] intentionally omitted <==

C

O N

T

E

N T

About Uni-Bio

2

About this Report Director’s Message

2

4

Environmental, Social and Governance 5 Communication with Stakeholders 6 9

Responsible Operation Valuing our Employees

Valuing our Employees 13 Environmental Protection 17 Community Engagement 21 Performance on Compliance 21 Overview of Key Performance Indicators 23 Reporting Content Index of 27

Environmental, Social and Governance Reporting Guide

ABOUT UNI-BIO

Uni-Bio Science Group Limited (the “Group”) is a leading biopharmaceutical and healthcare company, whose core business involves the research and development, manufacturing and sale of innovative biopharmaceuticals that can treat human diseases. The Group is currently specialised in such fields as diabetes and related metabolic disorders, dermatology and ophthalmology. The Group is headquartered in Hong Kong and principally operates in mainland China.

The Group completed the streamlining of its structure during the year and has achieved greater operation efficiency. It strengthened direct sales channels, and established closer customer and business partner relationship with hospitals and sector specific distributors respectively to increase sales of core products. The Group continued to promote the research and development of new products, and invested approximately HK$41 million in drug research and development during the year. The Group will continue to promote business development, and expand sales channels to improve operation efficiency, thereby laying a solid foundation for future development in the pharmaceutical and medical care industry.

		Proportion of
Sales revenue (HK$’000)	Grossprofit margin	R&D expenses to revenue
208,776	86.7%	19.5%

ABOUT THIS REPORT

This report is the fifth Environmental, Social and Governance (“ESG”) Report (the “Report”) released by the Group. The Report describes the Group’s ESG policies, measures and performance during the year to help stakeholders understand the Group’s progress and direction for sustainable development issues. For details of the Group’s corporate governance, please refer to the section “Corporate Governance Report” in the Group’s annual report for the year ended 31 December 2020. The Report is prepared in Chinese and English and has been uploaded to the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (www.hkexnews.hk) and the Group’s website (www.uni-bioscience.com).

Scope of Reporting

The Report discloses the Group’s environmental, social and governance performance for the financial year from 1 January 2020 to 31 December 2020 (the “Year”). The Report covers the operations in relation to the biological and chemical pharmaceutical product business in the Group’s production bases in Beijing and Shenzhen (the “Plants”), as well as the Hong Kong head office. Looking forward to the future, the Group will review the scope of reporting on a regular basis, and gradually expand the scope of disclosure based on the principle of substantiality, thereby providing more comprehensive information for investors and stakeholders.

Reporting Standards

The Report is prepared in accordance with the Environmental, Social and Governance Reporting Guide (the “Guide”) set out in Appendix 27 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and is based on four reporting principles – materiality, quantitative, balance and consistency. The Report also reports on all the applicable social Key Performance Indicators (“KPIs”) under the “recommended disclosures” of the Guide. A complete index is attached to the final chapter of the Report to facilitate readers in browsing the Report by the Guide.

2 U n i - B i o S c i e n c e G r o u p L i m i t e d

Reporting Application of Principles Definition the Reporting Principles Materiality Importance shall be attached to The Group determined the impact reporting of the ESG issues that have of various ESG issues on the Group’s great impact on the Group and its operations through conducting stakeholders. a questionnaire with internal and external stakeholders. Based on the questionnaire results, the Group identified major environmental and social issues and made key disclosures. Quantitative KPI data must be measurable and Where feasible, the Group recorded comparative where appropriate. and estimated quantitative data and compared them with the previous performance where appropriate. To ensure the accuracy of environmental KPIs, the Group has commissioned an external consultant to conduct a carbon assessment, which follows national and international standards such as guidelines issued by the National Development and Reform Commission of the People’s Republic of China, ISO14064-1 and the Greenhouse Gas Protocol. Quantitative data on social KPIs in the Report are derived from statistical records of relevant departments. Balance The Group shall report its ESG By reporting in an objective and performance during the Year objectively unbiased manner, the Report ensures and truthfully. that the disclosed information reflects the Group’s overall ESG performance. Consistency The Group shall use consistent Where feasible, the Group used methodologies (including statistical consistent methodologies to keep method for disclosures) to prepare the statistics on the ESG data. Where any ESG report and allow for comparison of changes exist that may affect the relevant data, thereby understanding its comparison with previous reports, the business performance. Group has added annotations to the

Where feasible, the Group used consistent methodologies to keep statistics on the ESG data. Where any changes exist that may affect the comparison with previous reports, the Group has added annotations to the Report accordingly.

Opinion and Feedback

The Report is available in both English and Chinese. In case of discrepancy, the Chinese version shall prevail.

The Group relies on valuable feedback provided by stakeholders for improvement. Should you have any questions or suggestions, please send your opinions and feedbacks to info@uni-bioscience.com.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 3

DIRECTOR’S MESSAGE

As a biopharmaceutical company, the Group has been providing high-quality treatment to patients through research, development and manufacturing of various healthcare products that can treat human diseases and contribute to the society. In order to cope with various diseases and the global epidemic in future, the Group is committed to bringing innovative and high-quality healthcare solutions that enhance the life quality of patients and promote the health and well-being of communities. The Group is fully aware that sustainable development governance and risk management have a significant impact on its operations. The Group will strengthen Board supervision and accountability on ESG issues and intend to minimise ESG risks through the risk management and internal monitoring system. Therefore, the Group can identify all kinds of sustainable development risks, as well as supervise the implementation of various sustainable development policies and measures across different departments.

Maintaining good communication with stakeholders plays an important role in the business development of the Group. During the Year, the Group has commissioned an external consultancy company to conduct a questionnaire with relevant stakeholders for identifying and determining the ESG issues that have a significant impact on the Group. The results of the questionnaire serves as an important basis for the Group to formulate its sustainable development strategy in the future, and they were also taken as a focus of disclosure in the Report to give the stakeholders a better understanding of the Group’s sustainable development performance.

The quality of drugs has a direct impact on patient health. Therefore, the Group needs to maintain the quality of products continuously and ensure the drug use safety of patients. The Group has developed various management strategies and standard operating procedures (SOP) to standardise the pharmaceutical production process and ensure that the quality of our products meets standards. Besides, the Group also strives to maintain a good relationship with our employees and ensure their occupational health and safety, for which various employment benefit policies and safety production measures have been established. To address the use of hazardous chemicals during operations, the Group has also developed various contingency plans and taken early warning and preventive measures to cope with unexpected environmental and safety accidents.

During the Year, the Group’s operations were severely affected by the novel coronavirus (“COVID-19”) pandemic. In response, the Group has implemented various measures to mitigate the impact of the COVID-19 pandemic on the Group. In administrative aspect, the Group has integrated the risk of COVID-19 into its corporate risk management system. The Group’s business continuity plans include COVID-19 in the Group’s reporting and management guidelines. In supplies management perspective, the Group maintained relationships with major supply chain partners to ensure effective control of imports and exports in compliance with transportation control regulations. Responding to public policy, the Group also supported and fully facilitated government-backed coronavirus job retention scheme for furloughed staff.

Looking forward, as regulatory authorities and investors increasingly pay attention to our efforts in promoting sustainable development and coping with relevant risks, the Group will continue to review and improve environmental and social policies and measures. The Group will also continue to strengthen communication with stakeholders so as to better understand their expectations and views on the operations of the Group and to identify and respond to potential environmental and social risks as early as possible, thereby creating longterm values for shareholders and society.

Kingsley Leung

Chairman

Uni-Bio Science Group Limited

4 U n i - B i o S c i e n c e G r o u p L i m i t e d

ENVIRONMENTAL, SOCIAL AND GOVERNANCE

The Group firmly believes that good corporate governance is becoming increasingly important to the Group’s long-term business development. The Board is responsible for corporate governance and is fully in charge of formulating the Group’s strategies and monitoring the Group’s operations, so as to achieve the Group’s strategic goals.

As regulatory authorities and stakeholders continually increase their expectations for sustainable development governance, the Group is committed to further improving its work on sustainable development, and will consider setting up an environmental, social and governance committee in the future, and clarifying the committee’s scope of powers and available resources. The members of the committee will include the Group’s core management personnel, so as to ensure the effective management of sustainable development issues.

Risk Management

The Group is committed to the implementation of effective risk management and internal monitoring system to safeguard the Group’s assets and interests. The Board is fully responsible for the Group’s internal monitoring system and reviews its effectiveness on a regular basis, and continuously identifies, evaluates and manages the risks. Through the Audit Committee, the Group conducted an annual review of the Group’s risk management and internal system. Based on the review results, the Board considers the Group’s risk management and internal control system are adequate and effective.

Risk Management Process

==> picture [389 x 82] intentionally omitted <==

----- Start of picture text -----

Establishing risk
Identifying and sorting outEvaluating managementstrategy and risk changesMonitoring
potential risks identified risks internal monitoring and reporting
risks
process
----- End of picture text -----

==> picture [7 x 7] intentionally omitted <==

The Group has identified two operational risks related to social issues, including the potential danger of production accidents and the risk of loss in the process of delivering sales invoices to customers. The Group has established corresponding risk management strategies and internal management measures to reduce the operational risks and their impacts on the Group. Details of risk management are as follows:

Operational risks

Internal management measures

Loss of invoice Goods and invoices are shipped and mailed separately with tracking for status of shipment and postage. Potential danger of production accident Safety working groups have been established to conduct regular checks and inspections.

The Group is aware that its current risk management and internal control do not fully cover ESG issues. Looking ahead to the future, the Group plans to incorporate sustainable development issues into the risk management system to effectively identify and manage related issues.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 5

COMMUNICATION WITH STAKEHOLDERS

Communication with stakeholders helps stakeholders understand the Group’s management policy for sustainable development and allows the Group to understand stakeholders’ expectations and views. Stakeholders’ opinions will help the Group review its performance and potential risks and further improve its business development and management.

Major Ways of Communication with Stakeholders During the Year

	Directors and Employees		Customers
•	Maintaining two-way communication	•	Maintaining good communication with
	through various channels, including internal		customers via telephone and Email
	communications, staff activities and staff
	opinion collection boxes, etc.	•	Establishing the customer complaint
			mechanism to ensure high customer
			satisfaction
		•	Organising relevant meetings with customers
	Suppliers and Business Partners		Communities
•	Evaluation and review of candidate suppliers	•	Encouraging employees to participate in
			volunteer and fund-raising activities
•	Field investigation and on-site audit of key
	suppliers	•	Making donations to charities
•	Collecting supplier-related information during
	daily process and regularly check compliance
	and output performance of suppliers
	Investors and Shareholders		Regulatory Authorities
•	Convening the annual meeting of shareholders	•	Conducting management as required by
	every year to provide opportunities for		national laws and regulations
	shareholders to ask questions and reflect their
	views to directors	•	Responding to the inquires of regulatory
			authorities
•	Reporting to shareholders and investors on
	business operations and financial position of
	the Group through annual reports and other
	information disclosures
•	Fielding daily telephone and Email inquiries

6 U n i - B i o S c i e n c e G r o u p L i m i t e d

Materiality Assessment

To identify the environmental and social issues that are critical to the Group and the stakeholders, the Group commissioned an external consultancy company BMI Environmental Consultancy Limited (“BMIEC”) to collect the opinions of stakeholders through an online survey. All questionnaires were conducted anonymously to ensure that participating stakeholders can express their views and expectations freely and honestly.

BMIEC identified 21 issues that were most relevant to the Group’s business, covering four major areas, namely “environmental protection”, “employment and labour practices”, “operational practices” and “community investment”, and used them as a basis for this questionnaire. The stakeholders were asked to rate the importance of the 21 issues to individuals and the Group’s influence on the environment and society. Based on the questionnaire results, BMIEC conducted materiality analysis and identified the materiality issues.

Issue Category	Issue
Environmental protection	1.	Managing greenhouse gas emissions
Environmental protection	2.	Managing exhaust emissions
Environmental protection	3.	Wastewater discharge management
Environmental protection	4.	Saving water/improving water efficiency
Environmental protection	5.	Waste management
Environmental protection	6.	Saving energy/improving energy efficiency
Environmental protection	7.	Managing the impacts of business operations on the
		environment and natural resources
Employment and labour practices	8.	Establishing a comprehensive employment system
Employment and labour practices	9.	Providing an equal and diversified work environment to
		eliminate discrimination or sexual harassment in the workplace
Employment and labour practices	10.	Providing a healthy and safe working environment for employees
		and preventing occupational diseases and work-related injuries
Employment and labour practices	11.	Providing training for employees to improve their knowledge
		and skills
Employment and labour practices	12.	Preventing child or forced labour
Operational practices	13.	Evaluating and managing environmental and social risks of the
		supply chains
Operational practices	14.	Establishing a GMP certification system to ensure drug quality
Operational practices	15.	Take responsibility for products or services provided
Operational practices	16.	Protecting privacy
Operational practices	17.	Implementing the advertising supervision and drug labeling
		review system to regulate advertising and ensure proper use of
		products by consumers
Operational practices	18.	Putting an end to corruption
Operational practices	19.	Establishing anti-corruption whistle-blowing channels and
		procedures, and promising not to disclose the whistleblower’s
		privacy
Community investment	20.	Understanding the needs of the community and managing the
		impact of operations on the community
Community investment	21.	Investing resources for community development

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 7

The following graph is the materiality matrix of the Group. The 12 issues in the upper right box are the high materiality issues of the Group.

ESG materiality matrix of the Group

==> picture [383 x 492] intentionally omitted <==

----- Start of picture text -----

5
12
10
14
4 8 15
3
3 1 2 16 919 6 18 5
11
High materiality
13 4 17
7
2
20
21
1
Not material Low materiality
0 1 2 3 4 5
The Group’s impact on the environment and society
Issues of high materiality (ranked by importance)
Rank No. Issue
High importance 14 Establishing a GMP certification system to ensure drug quality
15 Take responsibility for products or services provided
12 Preventing child or forced labour
8 Establishing a comprehensive employment system
5 Waste management
3 Wastewater discharge management
18 Putting an end to corruption
10 Providing a healthy and safe working environment for employees and preventing occupational diseases and work-related injuries
6 Saving energy/improving energy efficiency
9 Providing an equal and diversified work environment to eliminate discrimination or sexual harassment in the workplace
19 Establishing anti-corruption whistle-blowing channels and procedures, and promising not to disclose the whistleblower’s privacy
Low importance 11 Providing training for employees to improve their knowledge and skills
Importance of issue to stakeholders
----- End of picture text -----

8 U n i - B i o S c i e n c e G r o u p L i m i t e d

RESPONSIBLE OPERATION

The Group attaches importance to product quality and supply chain management, and maintains long-term relationship of mutual trust with customers. Therefore, the Group has developed a number of policies and measures to manage the risks related to supply chain, quality management and corporate integrity.

Product Responsibility

As a pharmaceutical enterprise, the Group is deeply aware of the importance of product quality. The Group’s pharmaceutical manufacturing plants in Beijing and Shenzhen have passed the GMP (“Good Manufacturing Practices”) certification, and have established all kinds of procedures under the GMP system to manage the Group’s pharmaceutical production process, including quality assurance, verification and confirmation, shipment and recall, and production technology. The Group has implemented a series of policies and measures to ensure that the products comply with the quality standards during the development, production and sales process, thereby providing consumers with quality products. Further, the Group continues to invest in research and development of innovative and patented products that have potential and commercial values.

Product Responsibility Measures

Product Development Preliminary study for PTH pharmacokinetics/pharmacodynamics study have been completed during the Year, with clinical data providing support for proceeding to the formal study. It is predicted that a minimum of 72 cases is required for the formal study, with the clinical study using a two way crossover design. This helps the formal study in mitigating risks, reducing cases, lowering research costs, and increasing the possibility of equivalence.

Preliminary study has commenced for E4. The Group has selected a clinical hospital with extensive experience in pharmacokinetics of glucoselowering agents as a research site. The clinical study design includes pharmacodynamics monitoring of blood glucose levels based on pharmacokinetics, and strives to obtain convincing preliminary study results, through which the Group may communicate in advance with the National Medical Products Administration Center for Drug Evaluation to reduce the clinical study design cycles and number of cases for phase III trials, in order to lower clinical trial expenses and save research cycles.

Quality Management In order to ensure the quality level of products, the Group has revised and implemented the Production Process Management SOP to standardise the requirements on the staff, materials, equipment, technology and environment during the production process, in an attempt to prevent cross-contamination and errors in production.

The Group also established the Finished Product Distribution Management to standardise the distribution process of finished products, where finished products can be distributed only after qualified for inspection and approved by the Quality Assurance Department. In accordance with the Administrative Regulations for Non-Conforming Products, if there is a quality problem during the materials, inspection, storage and production process, staff of the Production Department shall report to the Production Department and the Quality Assurance Department according to the Deviation Management SOP, then analyze the reasons and formulate solutions.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 9

Product Responsibility Measures

Product Labeling and Advertisement

To ensure the labels, instructions and other packaging materials of the products comply with the requirements of relevant laws and regulations, the Group formulated the Administrative Regulations for Printed Packaging Materials, and specified the process for handling and making the printed packaging materials. The Quality Assurance Department will report the printed packaging materials to the drug regulatory authority for review, so as to guarantee the customers’ accurate understanding of the labeling content and proper use of the products.

The Group strictly complies with relevant laws and regulations on drug advertisements to ensure that promotional information are accurate, professional and compliant, and promises not to publish advertisements in mass media or publish prescription drug advertisements to the public by giving away medical publications and pharmaceutical journals. The Group will consider formulating policies in the future to regulate advertising behavior.

Complaint and Product Recall

In order to maintain customer satisfaction with the Group’s products, the Group formulated the Administrative Regulations for Quality Complaints to handle customer complaints about product quality. Upon receipt of a customer complaint, the Quality Assurance Department will, based on the content of complaint, cooperate with relevant production and testing department for investigation. The Quality Assurance Department will initiate the recall procedure according to the investigation results and make corresponding correction as soon as possible, as well as formulate measures to prevent the recurrence of the incidents in the future. No complaints were received during the Year.

To ensure the drug use safety of the public, the Group has developed the Administrative Regulations for Drug Recall and the Administrative Regulations for Drug Return to regulate the drug recall and return process. If the drug is likely to cause serious health hazards, it will be handled at the highest recall level, for which, the General Manager of the Group will take the full responsibility and give the order for drug recall. In that case, drugs with problems will be comprehensively recalled within 24 hours. During the Year, the Group had not conducted any product recall to be recalled for safety and health reasons.

Customer Privacy

The Group highly values customer privacy. The Group possesses a confidentiality system which strictly prohibits employees from disclosing any confidential information (including customer information) to any third parties to protect customer privacy. Employees who violate confidentiality shall be liable for any economic damages and take relevant legal liabilities.

10 U n i - B i o S c i e n c e G r o u p L i m i t e d

In terms of intellectual property rights, effective protection of intellectual property play an important role in securing the research and development of an enterprise. Accordingly, the Group stipulates that an employee must sign a Commitment Letter on Intellectual Property Ownership with the Group upon his/her employment to ensure the employee familiar with the Group’s provisions on intellectual property rights and to protect relevant benefits of the Group from infringement. At the same time, employees shall also abide by relevant provisions of the Employee Handbook relating to intellectual property rights, and protect relevant information from being leaked. The Group will continue improving relevant provisions on protection of the intellectual property rights to safeguard the interests of the partners.

CASE STUDY: THE PANDEMIC – THE GROUP’S BUSINESS FLEXIBILITY

The ongoing COVID-19 pandemic has forced companies and organisations to operate in unprecedented manners. The Group changed its face-to-face marketing plans to digitalised marketing. During the Year, the Group cooperated with Chengdu Medlinker Technology Company Limited to co-develop digital marketing and pharmaceutical e-commerce platform for the Group’s products. The Group aims to create an integrated healthcare service platform, which is expected to deliver much better service for patients and clinical practitioners, expanding its available marketing channels, and enhancing brand awareness. On top of traditional e-commerce, the collabouration with Medlink encompasses multiple disciplines including smart healthcare, disease management, patient and clinical practitioner education, academic marketing, healthcare big data, and drug tracing system, to create an integrated healthcare service platform. In addition, the Group is also proactively exploring partners such as Haodaifu (好大夫在線) and other respective platforms to address the unmet needs for online drug sales. GeneTime® is the first product of the Group to be introduced to this new channel. The social distancing and travel limitations brought by the COVID-19 outbreak have greatly changed the behavior of patients and consumers. The demands for online medical consultation and pharmacies have increased since then and the Group has taken proactive steps to pioneer new business models. The Group believes that the collabouration will become a strong future driver of GeneTime® sales as well as other products in the future.

Our COVID-19 response measures include enhancing preventive measures and providing strong support in terms of disinfection and protection for our partners. We have suspended public activities, events and all live interviews. We have also provided protective and disinfection products such as alcohol-based hand cleansers to our partner doctors and customers. All external and internal personnel are required to conduct temperature checks and wear masks when entering the Group’s operation sites and offices.

Anti-Corruption

The Group has been following a high standard of business ethics and integrity. The Group adopts a zerotolerance attitude towards any form of corruption such as bribery, corruption, extortion, fraud and money laundering. The Group establishes provisions on business gifts in the Employee Handbook, which prohibits employees from accepting business gifts in any amount and form from customers or other partners. Where an employee is unable to refuse, he/she should hand over gifts to the relevant departments of the Group in full. The Group has also established a complaint mechanism to encourage employees to monitor and report any corrupt behaviour of employees, whereby they can report to the person in charge of human resources or the General Manager on any non-compliance found. The Group will then carry out investigation into the relevant incidents and take the follow-up actions.

The Group specifically implements the comprehensive measures to secure the confidentiality of personal information and materials provided by whistleblowers. Unless consent for disclosure is given, whistleblower identity remains protected. The Group will ensure that employees are not subject to any form of threats, reprisals or inappropriate censures arising from reporting the aforesaid matters. Harassment or harm to whistleblowers is considered gravely inappropriate behaviour and verified cases will be severely dealt with.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 11

Supply Chain Management

During the Year, the Group has 55 suppliers, mainly from Beijing, Shanghai, Guangzhou and other places in mainland China, which mainly supply raw materials, packaging materials, reagents, accessories, labels and equipment. The Group formulates relevant process of suppliers selection in accordance with the Supplier Selection SOP and the Administrative Measures and Related Processes for Materials Purchase and Distribution.

The Group carefully selects quality suppliers through market comparison where possible. The Group evaluates and reviews candidate suppliers through the Questionnaire on Suppliers and the Supplier Qualifications Assessment Form on the basis of their performance record, experience, financial strength, reputation, ability to produce high-quality products and quality control effectiveness. For critical level materials, the Quality Management Department will also carry out testing and trial use, and evaluate according to the New Materials Test & Evaluation Form. The Group will also conduct regular on-site audits on key suppliers and carry out field investigation on manufacturing plants and facilities of the suppliers; other suppliers will be reviewed in writing, and the selection process of all suppliers will be confirmed by the Quality Assurance Department.

In order to reduce the environmental and social risks related to supply chains, the Group also has environmental and social requirements on the suppliers, including:

The Group’s Requirements on the Supplier in the Environmental and Social Aspects

• Product quality: GMP certificates for relevant pharmaceuticals, registration certificates for imported pharmaceuticals and ISO 9001 Quality Management System Certification

• Environmental protection: ISO 14001 Environmental Management System Certification and regular environmental monitoring

• Staff: Regular staff trainings and occupational health and safety of the staff

The Group collects relevant information about suppliers during the daily operation process and checks their compliance and output performance on a regular basis to ensure that suppliers consistently meet the relevant requirements of the Group. If a supplier fails to meet our criteria after assessment, its qualification as a supplier will be cancelled.

12 U n i - B i o S c i e n c e G r o u p L i m i t e d

VALUING OUR EMPLOYEES

The success of the Group depends on the joint efforts and contributions of our employees. The Group has established various personnel systems and formulated related policies to provide a safe, comfortable and healthy working environment for employees and to ensure that all employees can receive reasonable remuneration, benefits, training and promotion opportunities.

Health and Safety

The Group deeply understands the importance of occupational health and safety of employees. The Occupational Health Management SOP and the Emergency Plan for Hazardous Chemical Accidents have been established to ensure the health and safety of employees and the protection from occupational hazards.

CASE STUDY: SAFEGUARDING OUR EMPLOYEES DURING COVID-19

COVID-19 threatens lives and creates uncertainties. The Group has responded with resilience and maintained operations where the safety of our employees was not affected. During the Year, we had zero cases of employee infection.

To safeguard the health and safety of our employees, the Group followed the latest government advice and provided regular advice and guidelines to our employees. We implemented various response measures during the height of the outbreak such as flexible working arrangements (e.g. work from home policy) and using technological infrastructure to maintain operations. Employees were required to conduct temperature checks before work and wear masks at the workplace. The Group implemented special internal COVID-19 arrangements to help certain employees placed on leave to maintain livelihoods. Employees who had travelled overseas were also required to give prior notice and prohibited from travelling to high-risk areas unless on vital business. Enhanced cleaning was conducted in office areas and protective equipment such as masks, disinfectants, essential oils and disposable gloves were provided in our offices.

Occupational Disease Prevention and Control

In order to prevent, control and eliminate relevant risks related to occupational diseases, the Group has implemented the Occupational Health Management SOP, which establishes the responsibility system, rules and regulations and operating procedures for prevention and control of occupational disease. The purpose is to supervise and inspect the prevention and control work for occupational diseases during operations and eliminate the occupational hazard accidents and risks.

Based on the Responsibility System for Prevention and Control of Occupational Diseases, the Group set up a leading group of occupational health work under the leadership of general manager of the Plants, which carries out the occupational disease prevention and control among employees, formulates and implements the annual occupational disease prevention and control plan and solution. The Group also provides employees with an annual report on the work plan for occupational disease prevention and control and its implementation, actively listens to employees’ opinions on occupational safety and health measures, and improve relevant system and measures.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 13

The Group provides occupational health examination and establishes occupational health records for employees according to the category of occupational disease hazard factors, level of exposure, etc. If an employee is suspected of the occupational disease during the health examination, the Group will arrange the employee to accept treatment as soon as possible. The Group has entrusted an external inspection agency to test the production environment and identify the occupational hazard factors.

In accordance with the Hazard Warning and Notification System of Occupational Diseases, the Group shall truthfully disclose the potential occupational disease risks (such as exposure to dust, noise, high temperature and harmful gases) while recruiting an employee, and shall specify such risks in the labour contract. The Group also set up a bulletin board in the production workshop to announce the rules and regulations, operating procedures and emergency measures for prevention and control of occupational diseases, as well as the potential or generated hazards of occupational diseases and the potential risks. In view of the risk of potential hazards, the Group will provide employees with relevant protective measures such as dust masks or gas masks, sound insulation measures and heat insulation equipment.

Emergency Response for Hazardous Chemicals

In order to strengthen the prevention of hazardous chemical accidents and reduce the risks, the Group has formulated the “Emergency Plan for Hazardous Chemical Accidents”, which stipulates that the Equipment Department should monitor and control the key hazard sources of the production sites every day. The Group has implemented preventive and early warning measures, including daily irregular inspection of hazard sources in workshops and warehouses, and has also established the safety inspection system for job positions of hazardous nature. If an unexpected incident occurs, the on-site personnel will report and make an alarm according to the emergency plan and the five-level response procedures, and respond to the incident based on how controllable it is. The purpose is to bring the source of the hazard under control in a timely manner, rescue any casualties and evacuate all personnel, and eliminate the potential dangers, thereby reducing the impact on the business operations and the safety and health of employees.

Safety Training and Emergency Drill

The Group provides regular occupational health trainings to its employees, so as to enhance their awareness of occupational safety and health and to teach them how to use the protective equipment and personal protection articles properly. The Group also holds fire drills and emergency evacuation drills on a regular basis to enhance the employees’ awareness of emergency response.

No work-related accident or work-related death occurred to the Group during the Year.

14 U n i - B i o S c i e n c e G r o u p L i m i t e d

Employment

The Group firmly believes that having a sound employment system will enable us to attract and retain talents. The Group has formulated the Employee Manual and the Human Resource Management Manual, which specify the recruitment, dismissal, salary, promotion, working hours, vacation, anti-discrimination, equal opportunities, benefits and other treatments for employees.

Recruitment and Dismissal

Remuneration and Benefits

The Group carries out recruitment according to the principles of impartiality, fairness and equal competition. The personnel department will provide persons who are employed with orientation to help them understand the rules and systems of the Company, work contents and requirements, etc.

The Group and its employees may also terminate their labour contracts as required. Employees who voluntarily resign shall make an application according to resignation procedures.

The Group is committed to maintaining its competitiveness in the remuneration market in the industry and determines the remuneration of its employees based on their performance.

The Group also provides a benefit system to its employees in accordance with government regulations, including making contribution to the social and labour insurance funds, the housing provident fund, endowment insurance, medical insurance, employment injury insurance, maternity insurance, unemployment insurance funds for employees. The Group provides employees with dormitory, meals and holiday allowances and organise annual check-up for them.

Promotion

Vacation

According to the performance management system, the Group provides employees with promotion opportunities. The Group regularly conducts performance assessment of its employees, and employees with outstanding performance will be given priority in promotion. In addition, national professional qualifications or academic qualifications at a higher level obtained by employees after selfstudy may also be taken into consideration for promotion.

In addition to statutory holidays, employees of the Group are also entitled to various paid holidays, including annual leave, marriage and funeral leave, maternity leave and nursing leave. Employees who have worked in the Group for more than one year are entitled to seven to fourteen days of annual leave each year, while employees who have worked for the Group for over ten years are entitled to up to twenty days of annual leave each year.

The Group is committed to providing a diverse and inclusive work environment for employees. It has implemented the employment system in accordance with the Labour Law of the People’s Republic of China and other laws and regulations, and does not allow discrimination by employees in any form based on gender, age, nationality, marital status, physical condition or position. As an employer advocating equal opportunities, the Group is committed to providing equal employment opportunities for people with disabilities so that they can integrate into society. During the Year, the Group employed a total of one person with disabilities to mainly assist in the Plants’ operation of the Group.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 15

Looking ahead, the Group will review the current employment system, and review and improve its diversification-related policies.

In order to foster good relationships with employees, the Group regularly organises various team building and employee activities, including sports meeting, travel, birthday parties and welcome parties for new employees, to enhance employees’ sense of belonging to the Group. The Group has established suggestion box management rules to collect opinions from employees for helping the Group improve the employment system and employee-related policies.

Development and Training

The Group attaches great importance to the personal development of employees, providing various knowledge and skill training opportunities according to the needs of employees and corporate needs. The Group formulates annual training plans and related measures for its employees and individual departments in accordance with the Employee Manual and the Human Resource Management Manual.

Training Type	Training Contents	Training Contents
Internal training	•	Corporate culture and company management system;
	•	Safety knowledge and operation training;
	•	GMP knowledge training; and
	•	Professional skills, operation, safety knowledge and skills training.
External training	•	Regulation application training organised by the state, the training center of
		Beijing Medical Products Administration, and various industry associations;
	•	Professional and technical training provided by equipment manufacturers;
	•	Industry exchange and training in technologies; and
	•	Professional quality training.

In order to encourage employees to actively pursue personal career development, the Group may take the training results of employees as an important basis for year-end performance evaluation and promotion. In addition to the priority in promotion and salary increase, outstanding employees may obtain more opportunities for future external training.

During the Year, there were 125 employees of the Group who received training, which accounted for 43% of the total number of its employees. During the Year, the average training hours per employee were 1.1 hours.

16 U n i - B i o S c i e n c e G r o u p L i m i t e d

Labour Standards

The Group prohibits the employment of child labour in its operations. In accordance with the Employee Manual and the Human Resource Management Manual, the employment of child labour under the age of 16 is strictly forbidden by the Group. The Group’s personnel administration department checks the identity documents of the applicants during the recruitment process. If it is found that child labour is employed by mistake, the Group will immediately terminate their employment contracts and contact their parents to take them home.

The Group also prohibits forced labour. In accordance with the overtime work management rules in the Employee Manual and the Human Resource Management Manual, all overtime work is subject to the submission of a written application, and approval by the department head and the general manager. All overtime work is compensated in the form of compensatory time off or overtime allowance. In addition, the Group strictly prohibits any unfair restrictions on the employment relationship between employees and the Group, such as withholding deposits or identity documents, and restricting personal freedom of employees and forcing them to work by means of violence and coercion.

ENVIRONMENTAL PROTECTION

The Group attaches great importance to the use of resources and emissions in its operation and the impact of its operation on the surrounding environment. The Group has formulated various environmental protection policies to reduce the negative impact of its operation on the environment and improve the energy efficiency of its operation.

Emissions

The Group pays attention to the environmental impact of emissions generated in its operation. The Group has formulated the SOP for Management of Three Wastes, the Internal Guidelines of the Group for Environmental Protection and Use of Natural Resources, and the Hazardous Waste Management Plan to standardise the treatment processes of various hazardous wastes, solid wastes, wastewater and exhaust gas. In addition, the Group regularly conducts exhaust gas and wastewater testing to ensure safe discharge and meet relevant testing standards.

Waste and Liquid Waste

In order to ensure the proper disposal of waste from operation and production, the Group disposes of waste in accordance with the SOP for Management of Three Wastes and the Hazardous Waste Management Plan. Non-hazardous wastes, such as general wastes and office wastes, are collected and disposed of by the environmental hygiene department. Liquid wastes and other hazardous wastes are generally stored by the Plants in corresponding containers, such as reinforced plastic buckets, or lidded paper buckets or iron buckets, with labels indicating corresponding hazardous wastes, and are finally collected and treated by qualified waste treatment companies. Liquid wastes such as mercury-containing liquid waste and liquid waste of chemical reagents, must be neutralised and steam sterilised before being discharged. All hazardous wastes are recorded in the Waste Handover Record for future review.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 17

During the Year, the Group generated a total of 2.72 tonnes of hazardous waste and approximately 343.37 tonnes of non-hazardous waste.

	Waste Type	Emissions in 2020	Unit
	Mercury-containing liquid waste	0.12
Hazardous Waste	Liquid waste of chemical reagents Empty reagent bottles	1.97 0.38
	Liquid waste from tests	0.25	Tonne
Non-Hazardous Waste	Cartons and woven bags Kitchen waste Domestic waste	0.47 122.4 220.5

Wastewater

During the Year, the Group generated a total of 19,021 m[3] of wastewater.

Wastewater discharge in	2020	Unit
19,021		m3

In order to properly treat the sewage discharged from the production workshop and boiler room, the Group has completed the construction of a sewage treatment system in the Plants during the Year, which will be used to treat the production wastewater and domestic wastewater of the Plants.

Exhaust Gas

Air emissions from the Group mainly come from the operation of the production base in Beijing and Shenzhen, including respirable particulate matter from the production process, pollutants released from the combustion of natural gas by gas-fired boilers, and exhaust gas produced from the use of automobiles. Exhaust gas must be purified before being discharged. According to the SOP for Management of Three Wastes, the Group regulates the emission of exhaust gas. The gas generated from the fermentation area, and the positive bacteria control area of the laboratory of the Group are treated by filters before being discharged.

During the Year, exhaust gas arising from the combustion process of the Group mainly include nitrogen oxides (NOx), sulfur oxides (SOx) and respirable particulate matter (PM). As set out in the table below, the Group generated 6.33 kg, 0.19 kg, and 0.47 kg of NOx, SOx and PM during the Year respectively.

Emission Type	Emissions in 2020	Unit
Nitrogen oxides (NOx)	6.33
Sulfur oxides (SOx)	0.19	Kg
Respirable particulate matter (PM)	0.47

18 U n i - B i o S c i e n c e G r o u p L i m i t e d

Greenhouse Gas (“GHG”)

During the Year, the Group commissioned a consultancy company to conduct a carbon assessment to quantify GHG emissions (or “carbon emissions”) generated by its operations. The quantitative process is based on the guidelines issued by the National Development and Reform Commission of the People’s Republic of China and international standards such as ISO14064-1 and the Greenhouse Gas Protocol.

The Group’s carbon emissions come mainly from indirect emissions from purchased electricity (scope 2), accounted for 80% of the total emissions. For the main sources of carbon emissions, the Group will continue to assess, record and disclose its greenhouse gas emissions and other environmental data every year, and review the effectiveness of existing measures, which further help to set the emission reduction targets in the future. The Group will consider formulating relevant policies and emission reduction targets for the management of greenhouse gases in the future, so as to reduce greenhouse gas generated by the operation.

Total greenhouse	Carbon emissions	Greenhouse gas intensity
gas emission	frompurchased electricity	(based onproduction value)
3,431 tCO2e	accounted for: 80%	17.9 tCO2e per RMB million

Environment and Natural Resources

Chemical leakage accidents have a great impact on the surrounding environment. Therefore, the Group has formulated the Hazardous Waste Management Plan and established the Environmental Management Committee. In addition to arranging and implementing the environmental protection management of the Plants, the committee also handles the abnormal events in environmental protection management, and reduces the impact of the operation on the surrounding environment.

Duties of the Environmental Management Committee

Position	Responsibility	Responsibility
Director of the Environmental	•	Leading environmental management work of the Group; and
Management Committee
	•	Approving the execution documents of all environmental
		management work.
Executive Director	•	Assisting the Director of the Environmental Management Committee
of the Environmental		to coordinate the environmental management work of various
Management Committee		departments of the Group.
Secretary General	•	Implementing environmental management policies;
of the Environmental
Management Committee	•	Working with government departments; and
	•	Arranging training in relation to internal environmental management.
Members of the Environmental	•	Measuring the relevant data of environmental management.
Management Committee

During the Year, the Group built and improved its sewage treatment system and improved its sewage treatment process, with total expenditure of RMB1.02 million.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 19

Use of Resources

In order to ensure the effective use of resources in the course of operation, the Group has formulated the Corporate Energy Conservation Management System and the Internal Guidelines of the Group for Environmental Protection and Use of Natural Resources, which specify the policies on resource management and regulate resource management.

Use of Resources	Saving Measures	Saving Measures
Water consumption	•	Use water economisers and avoid keeping taps running for a long
		time, and regularly check water equipment to ensure that there is no
		water leakage;
	•	When possible, clean vehicles with buckets of water and avoid leaving
		the hose running; and
	•	Check the water supply pipes regularly. If pipe damage is found, the
		pipe shall be repaired and replaced in a timely manner, so as to reduce
		water leakage and ensure that no water is wasted.
Electricity	•	Use more environmentally-friendly and energy-saving electrical
		appliances;
	•	Turn off the power supply of idle electrical appliances and avoid
		leaving appliances on standby; and
	•	Check the electric power facilities regularly, and report any leakage or
		trip found, for repair, in a timely manner.
Packaging material	•	Packaging materials shall be printed, distributed and used in
		accordance with the SOP for Packaging Materials Management
		in Production Workshops to ensure the proper use of packaging
		materials; and
	•	If repackaging is required due to any abnormal condition in the
		packaging and production process, the repackaging shall be carried
		out only after inspection and investigation by and approval from
		relevant personnel, and shall be recorded for future review.

During the Year, the resources used by the Group mainly included fossil fuels burned in the Plants and electricity, water, raw materials and packaging materials consumed in our daily operation. The consumption of electricity, which is a form of indirect energy, ranked first among all consumed energy of the Group, and accounted for approximately 54% of the total energy consumption of the Group.

Total direct	energy consumption	Total indirect energy consumption
2,023	MWh-equivalent	3,554 MWh

For the use of other resources, please see the section headed “OVERVIEW OF KEY PERFORMANCE INDICATORS” in relation to environmental performance.

Looking ahead, the Group will conduct more refined control and management to improve the efficiency in the use of resources in the process, and gradually set quantified objectives based on the resource consumption during the Year.

20 U n i - B i o S c i e n c e G r o u p L i m i t e d

COMMUNITY ENGAGEMENT

The Group is committed to fulfilling its corporate social responsibility and encouraging its employees to give back to the society. The Group has formulated the Community Interest Policy, which specifies policies and objectives of the Group on social investment. During the Year, the Group donated HK$14,000 worth of antibacterial hand gel to hospitals and healthcare facilities. Looking ahead, the Group will consider identifying more institutions and projects that could be benefited from our donations, so as to further increase social participation and bring positive impact on the society.

Objectives under the Community Interest Policy

1. Creation of jobs;

2. Driving the development of local related industries;

3. Improving local infrastructure construction;

4. Public welfare and charity;

5. Employment promotion; and 6. Local economic development.

PERFORMANCE ON COMPLIANCE

The Group understands that violation of laws and regulations will lead to material impacts such as administrative penalties and even suspension of business for rectification. The Group has formulated policies and standard operating procedures in accordance with relevant laws and regulations to provide clear working guidelines for employees. The following laws and regulations have a significant impact on the Group. During the Year, the Group has complied with relevant laws and regulations, and there was no violation (including not receiving any corruption-related litigations against enterprises or employees).

Relevant laws and regulations that Aspects have significant impacts on the Group

• Emissions • Environmental Protection Law of the People’s Republic of China • Law of the People’s Republic of China on Prevention and Control of Water Pollution

• • Law of the People’s Republic of China on the Prevention and Control of Atmospheric and Pollution

• Employment • Labour Law of the People’s Republic of China • Labour Contract Law of the People’s Republic of China • Law of the People’s Republic of China on the Protection of Women’s Rights and Interests

• • Regulations Concerning the Labour Protection of Female Staff and Workers

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 21

	Relevant laws and regulations that	Relevant laws and regulations that
Aspects	have	significant impacts on the Group
Health and safety	•	Production Safety Law of the People’s Republic of China
	•	Law of the People’s Republic of China on the Prevention and Control of
		Occupational Diseases
	•	Fire Protection Law of the People’s Republic of China
Labour standards	•	Labour Law of the People’s Republic of China
	•	Law of the People’s Republic of China on the Protection of Minors
Product liability	•	Product Quality Law of the People’s Republic of China
	•	Patent Law of the People’s Republic of China
	•	Pharmaceutical Administration Law of the People’s Republic of China
	•	Good Manufacturing Practices for Pharmaceutical Products
	•	Trademark Law of the People’s Republic of China
	•	Advertising Law of the People’s Republic of China
	•	Interim Measures for the Administration of Censorship of Advertisements
		on Drugs, Medical Devices, Dietary, Supplements and Formula Foods for
		Special Medical Purposes
	•	Provisions on the Administration of Pharmaceutical Directions and
		Labels
	•	Regulations for the Implementation of the Drug Administration Law of
		the People’s Republic of China
	•	Measures for the Administration of Drug Registration
	•	Measures for the Supervision over and Administration of Pharmaceutical
		Production
	•	Measures for the Supervision and Administration of Circulation of
		Pharmaceuticals
	•	Standards for Quality Control of Pharmaceutical Trading
	•	Measures for the Reporting and Monitoring of Adverse Drug Reactions
Anti-corruption	•	Anti-Unfair Competition Law of the People’s Republic of China
	•	Anti-Money Laundering Law of the People’s Republic of China

In order to ensure that the Group complies with the above laws and regulations, the Group has formulated various systems and policies, and requires its employees to comply with them. Meanwhile, the Group regularly provides training to employees to enhance their awareness of compliance with laws and regulations. The Group also strengthened the monitoring of potential risks to ensure that its business operation complies with laws and regulations.

22 U n i - B i o S c i e n c e G r o u p L i m i t e d

OVERVIEW OF KEY PERFORMANCE INDICATORS

Environmental Performance

Environmental Performance	Environmental Performance
Environmental KPIs		Amount	Unit
		2020
A1.1	The types of emissions and respective emissions	data
	Nitrogen oxides	6.33	Kg
	Sulfur oxides	0.19	Kg
	Respirable particulate matter	0.47	Kg
A1.2	Total greenhouse gas emission
	Scope 11	419.29	tCO2e
	Scope 22	2,902.87	tCO2e
	Scope 33	109.07	tCO2e
	Total greenhouse gas emission	3,431.23	tCO2e
	Greenhouse gas intensity (based on area)	0.17	tCO2e per square meter
	Greenhouse gas intensity	17.88	tCO2e per RMB million
	(based on production value)
A1.3	Total hazardous waste
	Total hazardous waste	2.72	Tonne
	Hazardous waste intensity (based on area)	0.14	Tonne per thousand square meters
	Hazardous waste intensity	0.01	Tonne per RMB million
	(based on production value)
A1.4	Total non-hazardous waste
	Total non-hazardous waste	343.37	Tonne
	Non-hazardous waste intensity (based on area)	17.07	Tonne per thousand square meters
	Non-hazardous waste intensity	1.79	Tonne per RMB million
	(based on production value)

• 1 Scope 1 includes emissions from the combustion of fossil fuels from stationary and mobile sources and fugitive emissions from refrigeration equipment. Although R-22 refrigerant used in refrigeration equipment is not included in the six greenhouse gases covered by the Kyoto Protocol, the emissions resulting from its leakage are also included in the assessment, so as to provide true and fair presentation of the information on greenhouse gas.

• 2 Scope 2 includes emissions from electricity purchased from power companies. Greenhouse gas emissions from purchased electricity are calculated based on the average national factor of greenhouse gas emissions of grid power in the PRC, which is derived from the Notice Regarding 2019 Carbon Emissions Reporting and Verification and Submission of the List of Key Emission Units in the Power Generation Industry (《關於做好2019年度碳排放報告與核 查及發電行業重點排放單位名單報送相關工作的通知》).

• 3 Scope 3 includes upstream and downstream emissions caused by employee business trips.

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 23

Environmental KPIs	Environmental KPIs	Amount	Unit
		2020
A2.1	Total energy consumption
	Natural Gas	1,906.48	MWh-equivalent
	Diesel	26.62	MWh-equivalent
	Gasoline	89.97	MWh-equivalent
	Electricity	3,031.85	MWh
	Heating	522.54	MWh-equivalent
	Total energy consumption	5,577.47	MWh-equivalent
	Energy intensity (based on area)	0.28	MWh-equivalent per square meter
	Energy intensity (based on production value)	29.06	MWh-equivalent per RMB million
A2.2	Total water consumption
	Total water consumption	51,027.02	Cubic meter
	Water consumption intensity (based on area)	2.54	Cubic meter per square meter
	Water consumption intensity	265.88	Cubic meter per RMB million
	(based on production value)
A2.5	Total packaging material used for finished	products
	Total amount of packaging materials	76.49	Tonne
	Packaging material intensity (based on area)	3.8	Tonne per thousand square meters
	Packaging material intensity	0.4	Tonne per RMB million
	(based on production value)

Social Performance

Number of Employees

By gender	Male Female	143 151
	Aged under 30	54
By age	Aged 30–40 Aged 41–50	150 63
	Aged above 50	27
	C-level executives	7
By rank	Senior executives Middle-level executives	9 76
	General staff	202
Total number of employees		294
Ratio of male to female employees		0.95:1

24 U n i - B i o S c i e n c e G r o u p L i m i t e d

	Number of new employees			New hire rate
By gender	Male Female	21 38		15% 25%
	Aged under 30	31		57%
By age	Aged 30–40 Aged 41–50	25 3		17% 5%
	Aged above 50	0		0%
	C-level executives	1		14%
By rank	Senior executives Middle-level executives	0 9		0% 12%
	General staff	49		24%
	Total	59		20%
	Number of turnovers			Employee turnover rate
By gender	Male Female	27 37		19% 25%
	Aged under 30	27		50%
By age	Aged 30–40 Aged 41–50	28 5		19% 8%
	Aged above 50	4		15%
	C-level executives	0		0%
By rank	Senior executives Middle-level executives	2 8		22% 11%
	General staff	54		27%
	Total	64		22%
Occupational Safety and Health
Performance			Total
Number and rate of work-related fatalities			0 (0%)
Number of work-related injuries			0
Lost days due to work-related injuries			0

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 25

					Average
		Percentage		Training	training
		of employees		hours	hours
Breakdown of the number of employees trained			trained	(hours)	(hours)
By gender	Male Female	56 69	39% 46%	178 153	1.2 1.0
	C-level executives	7	100%	2	0.3
By rank	Senior executives Middle-level executives	3 11	33% 14%	20 105	2.2 1.4
	General staff	104	51%	204	1.0
Total		125	43%	331	1.1
Region where the	supplier			Number of suppliers
is located	Number of suppliers		implementing relevantpractices
Shanxi		1		1
Chengdu		1		1
Xi’an		1		1
Guangzhou		14		14
Tianjin		4		4
Jiangsu		2		2
Shandong		2		2
Hebei		2		2
Beijing		24		24
Hunan		4		4
Total		55		55
Productquality			Total
Percentage of products recalled due to			0%
safety and health issues
Number of complaints related to products			0
or services

26 U n i - B i o S c i e n c e G r o u p L i m i t e d

REPORTING CONTENT INDEX OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING GUIDE

Aspects	Description	Page
A1 Emissions
General	Information on:	17, 21
Disclosure	(a) the policies; and
	(b) compliance with relevant laws and regulations that have a
	significant impact on the issuer relating to air and greenhouse
	gas emissions, discharges into water and land, and generation of
	hazardous and non-hazardous waste
A1.1	The types of emissions and respective emissions data	18, 23
A1.2	Greenhouse gas emissions in total (in tonnes) and, where appropriate,	19, 23
	intensity (e.g. per unit of production volume, per facility)
A1.3	Total hazardous waste produced (in tonnes) and intensity (e.g. per unit	18, 23
	of production volume, per facility)
A1.4	Total non-hazardous waste produced (in tonnes) and intensity (e.g. per	18, 23
	unit of production volume, per facility)
A1.5	Description of measures to mitigate emissions and results achieved	18–19
A1.6	Description of how hazardous and non-hazardous wastes are handled,	17
	reduction initiatives and results achieved
A2 Use of Resources
General	Policies on the efficient use of resources, including energy, water and	19
Disclosure	other raw materials
A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas	20, 24
	or oil) in total (in ’000 kWh) and intensity (e.g. per unit of production
	volume, per facility)
A2.2	Water consumption in total and intensity (e.g. per unit of production	24
	volume, per facility)
A2.3	Description of energy use efficiency initiatives and results achieved	20
A2.4	Description of whether there is any issue in sourcing water that is fit for	20
	purpose, water efficiency initiatives and results achieved
A2.5	Total packaging material used for finished products (in tonnes) and, if	24
	applicable, volume per production unit

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 27

Aspects	Description	Page
A3 The Environment and Natural Resources
General	Policies on minimising the issuer’s significant impact on the	19
Disclosure	environment and natural resources
A3.1	Description of the significant impact of activities on the environment	19
	and natural resources and the actions taken to manage them
B1 Employment
General	Information on:	15–16, 21
Disclosure	(a) the policies; and
	(b) compliance with relevant laws and regulations that have a
	significant impact on the issuer relating to compensation and
	dismissal, recruitment and promotion, working hours, rest
	periods, equal opportunity, diversity, anti-discrimination, and
	other benefits and welfare
B1.1	Total workforce by gender, employment type, age group and	24
	geographical region
B1.2	Employee turnover rate by gender, age group and geographical region	25
B2 Health and Safety
General	Information on:	13–14, 22
Disclosure	(a) the policies; and
	(b) compliance with relevant laws and regulations that have
	a significant impact on the issuer relating to providing a
	safe working environment and protecting employees from
	occupational hazards
B2.1	Number and rate of work-related fatalities	14, 25
B2.2	Lost days due to work injury	25
B2.3	Description of occupational health and safety measures adopted, how	13–14
	they are implemented and monitored
B3 Development	and Training
General	Policies on improving employees’ knowledge and skills for discharging	16
Disclosure	duties at work. Description of training activities
B3.1	The percentage of employees trained by gender and employee	16, 26
	category (e.g. senior management, middle management)
B3.2	The average training hours completed per employee by gender and	16, 26
	employee category

28 U n i - B i o S c i e n c e G r o u p L i m i t e d

Aspects	Description	Page
B4 Labour Standards
General	Information on:	17, 22
Disclosure	(a) the policies; and
	(b) compliance with relevant laws and regulations that have a
	significant impact on the issuer relating to preventing child and
	forced labour
B4.1	Description of measures to review employment practices to avoid child	17
	and forced labour
B4.2	Description of steps taken to eliminate such practices when discovered	17
B5 Supply Chain	Management
General	Policies on managing environmental and social risks of the supply	12
Disclosure	chain
B5.1	Number of suppliers by geographical region	12, 26
B5.2	Description of practices relating to engaging suppliers, number of	12, 26
	suppliers where the practices are being implemented, how they are
	implemented and monitored
B6 Product Responsibility
General	(a) the policies; and	9–10, 22
Disclosure	(b) compliance with relevant laws and regulations that have a
	significant impact on the issuer relating to health and safety,
	advertising, labelling and privacy matters relating to products
	and services provided and methods of redress
B6.1	Percentage of total products sold or shipped subject to recalls for	10, 26
	safety and health reasons
B6.2	Number of products and service related complaints received and how	10, 26
	they are dealt with
B6.3	Description of practices relating to observing and protecting	11
	intellectual property rights
B6.4	Description of quality assurance process and recall procedures	9
B6.5	Description of consumer data protection and privacy policies, how	10
	they are implemented and monitored

E n v i r o n m e n t a l , S o c i a l a n d G o v e r n a n c e R e p o r t 2 0 2 0 29

Aspects	Description	Page
B7 Anti-corruption
General	Information on:	11, 22
Disclosure	(a) the policies; and
	(b) compliance with relevant laws and regulations that have a
	significant impact on the issuer relating to bribery, extortion,
	fraud and money laundering
B7.1	Number of concluded legal cases regarding corrupt practices brought	21
	against the issuer or its employees during the reporting period and the
	outcomes of the cases
B7.2	Description of preventive measures and whistle-blowing procedures,	11
	how they are implemented and monitored
B8 Community	Investment
General	Policies on community engagement to understand the needs of the	21
Disclosure	communities where the issuer operates and to ensure its activities take
	into consideration the communities’ interests
B8.1	Focus areas of contribution (e.g. education, environmental concerns,	21
	labour needs, health, culture, sport)
B8.2	Resources contributed (e.g. money or time) to the focus area	21

30 U n i - B i o S c i e n c e G r o u p L i m i t e d